Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.

9 , 10 Despite failures in phase 3 randomized studies, PD-1 inhibitors showed a trend of prolonged survival and durable response in different treatment settings. 11 , 12 In the recently reported KEYNOTE-394 study, pembrolizumab plus best supportive care significantly prolonged OS (hazard ratio [HR] 0.79, 95% confidence interval [CI] 0.63-0.99, P = .0180) and PFS (HR 0.74, 95% CI 0.60-0.92, P = .0032) as second-line treatment in Asian patients with advanced HCC. 13 Immune-based combinations were also being investigated.

also in 53,322 other papers